Seattle biotech startup backed by Gates Foundation launches trial for snail fever vaccine

The first patient is dosed in a phase 1 trial for the SchistoShield vaccine against schistosomiasis. ( Kaiser Permanente Washington Health Research Institute Photo)

The first patient has been dosed with a vaccine for the tropical disease schistosomiasis, developed by Seattle biotech company PAI Life Sciences.

The phase 1 trial will assess the safety and immune response in healthy volunteers at Kaiser Permanente Washington Health Research Institute in Seattle.

Schistosomiasis, also called snail fever, is caused by parasitic flatworms that enter human skin in contact with contaminated water. Long term infections can cause damage to livers and kidneys, infertility, and bladder cancer.

A vaccine would build up the arsenal against the disease, which affects almost 240 million people in sub-Saharan Africa, the Middle East, Southeast Asia and the Caribbean. Treatments are available but often don’t shield against symptoms like headache and malaise, and many people experience recurrence, said PAI CEO Darrick Carter.

The condition “is second only to malaria among parasitic diseases with the greatest devastating economic impact,” said PAI’s vice president Sean Gray in a statement Tuesday announcing the trial launch. Many vaccine candidates have been tested, but “few have offered any significant protection,” said Gray.

The new protein-based vaccine can confer protection for up to eight years in primates, and antibodies are transmitted from mother to child, said Carter.

The advantage of PAI’s vaccine is that it is designed to affect all life cycles of the parasite in the body, from eggs to juveniles to adult worms. The vaccine targets a protein called calpain that cleaves other proteins and is thought to “remodel” the worm’s surface to help it evade the immune system.

Isolated schistosome worms under the microscope. (Afzal Siddiqui lab Image)

“By targeting this protein there would be less immune evasion. We are hitting a potential Achilles heel,” said Carter. The vaccine aims for eggs by killing almost all females, which have high levels of calpain on their surface and cause most of the pathology. And the worms that hatch are also damaged, interrupting transmission cycles.

See also  ‘Parallel Reality’ at the airport: High-tech screen displays personal flight info to multiple travelers

Not all the males are killed by the vaccine, but that is an advantage, said Carter. The males do not cause disease. And if a few stick around, they can keep the immune system activated and ready to attack any incoming females.

Texas Tech University Health Sciences Center researcher Afzal Siddiqui and his colleague invented the vaccine, which is licensed it to PAI.

PAI is also developing vaccines and treatments for other neglected conditions including tuberculosis and leishmaniasis, and sells adjuvants, immune-boosting substances added to vaccines. The 6-person company was founded in 2004 by Carter, who is also chief scientific officer at another Seattle vaccine company, HDT Bio.

The new “SchistoShield” vaccine is PAI’s first clinical trial. The trial is funded by the U.S. National Institute of Allergy and Infectious Diseases, the Bill & Melinda Gates Foundation, and a public-private partnership, the RIGHT (Research Investment for Global Health Technology) fund.

Hi, I'm Vikky Penn, currently working on msiu.info. This is my personal Blog, where I will share the tips and knowledge that I have learned. If you have any questions, please contact me at Email: [email protected]! Thank you !

Related Posts

Sea.citi merges with WTIA in combination of two civic-focused tech industry nonprofits in Seattle

Former Seattle Mayor Jenny Durkan announced the launch of Sea.citi in 2018. (GeekWire File Photo / Monica Nickelsburg) Sea.citi, a nonprofit that launched in 2018 with the…

Survey: 88% of U.S. startup leaders worried about fundraising, signaling slower growth ahead

Qualtrics / Delighted Graphic New research published Monday quantifies the growing sense of caution among U.S. startup leaders, as economic turmoil creates concerns about cash, and causes…

About to take early stage startup job? Amid concern of downturn, CEO says to ask these hard questions

Kieran Snyder of Textio at the 2019 GeekWire Awards. (GeekWire File Photo) In addition to the usual questions about pay and benefits and culture and so on,…

Why this Florida venture capitalist is touring Seattle’s tech scene

Pablo Casilimas. (Photos courtesy of Casimilias) When Pablo Casilimas gave his girlfriend, a travel nurse, a list of cities he would prefer to live in, he put…

Maveron raises $225M for its 8th fund to back more consumer-focused startups

The Maveron team. (Maveron Photo) The news: Maveron, a venture capital firm founded 24 years ago that invests in consumer-oriented startups, raised $225 million for its eighth…

Tech Moves: Flying Fish adds investor to lead new Canada office; Panopto, magniX hire CEOs

Tiffany Linke-Boyko. (Flying Fish Photo) — Flying Fish hired Tiffany Linke-Boyko as principal to lead a new Alberta hub, its first office outside of Seattle. The firm…

Leave a Reply

Your email address will not be published.